Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
Zhang, Peng-Fei; Xie, Dan; Li, Qiu.
Affiliation
  • Zhang PF; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Xie D; West China Biomedical Big Data Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  • Li Q; Prenatal Diagnosis Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
BMC Cancer ; 21(1): 35, 2021 Jan 07.
Article in En | MEDLINE | ID: mdl-33413230
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Cost-Benefit Analysis / Quality-Adjusted Life Years / Drug Resistance, Neoplasm / Prostatic Neoplasms, Castration-Resistant Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans / Male Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Cost-Benefit Analysis / Quality-Adjusted Life Years / Drug Resistance, Neoplasm / Prostatic Neoplasms, Castration-Resistant Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans / Male Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Country of publication: